3 Dividend Stocks to Buy Hand Over Fist in June

The article highlights three income-oriented investments: Pfizer at a 6.7% dividend yield, UPS at 7.7%, and the Schwab U.S. Dividend Equity ETF at 3.25%. It argues that Pfizer and UPS remain attractive due to undervaluation, strong dividend payouts, and improving business mix, while SCHD offers a diversified blend of income and growth with nearly 20% YTD performance as of June 4. The piece is broadly bullish on dividend-paying equities but is mostly opinionated commentary rather than market-moving news.

Analysis

The common thread is not “high yield” but yield backed by balance-sheet repair and pricing discipline. In both PFE and UPS, the market has already repriced away a lot of bad news, so the next leg is less about multiple expansion and more about whether management can convert portfolio pruning into sustained free-cash-flow stability. That matters because dividend screens tend to lag fundamentals: once payout coverage improves, these names can rerate faster than headline growth investors expect.

UPS is the cleaner second-order winner. Pulling back from low-margin volume should not just lift margins; it should also reduce operating complexity, improve service levels for higher-value shippers, and potentially force smaller competitors to compete on price rather than network quality. The hidden risk is that revenue-per-package gains can mask unit weakness for several quarters; if package counts keep sliding, fixed-cost deleverage can reappear quickly in a softer industrial economy.

Pfizer is more of a catalyst-driven turnaround than a classic yield play. The market is implicitly giving little credit to pipeline optionality, which creates upside if even one or two late-stage assets de-risk, but also means the stock remains vulnerable to any clinical or regulatory disappointment. Over the next 6-18 months, the dividend is likely to be a floor for the stock, but the ceiling depends on whether management can offset patent erosion with assets that materially extend growth beyond the current cycle.

SCHD is the broadest way to express the factor view, but it also dilutes idiosyncratic upside. The ETF’s exposure to quality dividend growers gives it a structural bid if rates drift lower or if investors rotate toward cash-returning equities, yet its holdings skew toward mature compounders rather than deep value turnarounds. The consensus is underestimating how much of the recent dividend-income trade is really a duration trade in disguise: if long rates back up again, the high-yield, slow-growth basket is the first place to get hit.

Key Decisions for Investors

• Long UPS vs short AMZN in a 3-6 month pair trade: express the view that logistics capital will continue migrating toward higher-margin enterprise shippers while Amazon internalizes more of its own delivery economics. Risk/reward is favorable if UPS maintains revenue-per-package expansion and AMZN’s cost savings are slower to show up in the P&L.
• Buy PFE on weakness for a 6-12 month trade, but size it as a catalyst basket position, not a secular growth bet. The dividend provides downside support; downside risk is concentrated in trial/readout headlines, so consider pairing with a biotech short or using call spreads instead of outright equity.
• Initiate a modest long SCHD as a core yield sleeve over 12 months, but hedge duration risk with a short position in a long-duration equity proxy if real yields re-accelerate. The best setup is if Fed cuts arrive without a growth scare, which would support both income and multiples.
• Sell covered calls on UPS against a long position for the next two earnings cycles. The stock has room to rerate on execution, but the high yield and slower volume growth cap upside; covered calls monetize implied volatility while preserving dividend carry.
• Avoid chasing the highest yielders purely on headline payout; favor dividend growers over static payers. In this tape, capital return quality matters more than absolute yield, and the market tends to reward balance-sheet-supported dividend growth over distressed income.